FDA
-
-
-
-
-
-
-
Monte Rosa Therapeutics (GLUE) Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat H
-
-
-
-
-
-
-
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
-
-
-
-
-
-
-
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
-
-
-
322,203 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

